A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase

Completed

Phase 2

Conditions

Measles

Treatments

Biological: Comparator: Measles, Mumps, and Rubella Virus Vaccine Live

Biological: V205C, measles, mumps, and rubella virus vaccine live

Study type

Interventional

Funder types

Industry

Identifiers

NCT00109278

2005_016

V205C-010

Details and patient eligibility

About

The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human albumin).

Full description

The duration of treatment is 6 weeks.

Enrollment

1,100 patients

Sex

All

Ages

12 to 18 months old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy children 12 to 18 months of age.

Exclusion criteria

Previous receipt of measles, mumps, rubella and/or varicella vaccine.
Prior infection or exposure to (within last 4 weeks) measles, mumps, rubella, varicella and/or zoster.
Any medical condition that might interfere with the immune response to the given vaccines (including HIV infection and/or cancer) or has undergone immunosuppressive (weakens your body's ability to fight infection) therapy.
History of seizures (convulsions)
Allergies to any component of the vaccine, including sorbitol, gelatin, or neomycin.
A recent (within the last 3 days) illness resulting in a fever (underarm temperature greater than 99.5° F [37.5° C]).